NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, Forecast & News

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals Inc (NASDAQ:ANIP) issued its quarterly earnings data on Wednesday, November, 6th. The specialty pharmaceutical company reported $1.23 earnings per share for the quarter, missing analysts' consensus estimates of $1.43 by $0.20. The specialty pharmaceutical company had revenue of $51.30 million for the quarter, compared to analyst estimates of $56.10 million. ANI Pharmaceuticals had a net margin of 7.58% and a return on equity of 28.28%. ANI Pharmaceuticals's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.29 EPS. View ANI Pharmaceuticals' Earnings History.

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for ANI Pharmaceuticals.

ANI Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Tuesday, December, 3rd. The company provided earnings per share (EPS) guidance of 5.06-5.23 for the period, compared to the Thomson Reuters consensus estimate of $5.14. The company issued revenue guidance of $209-212 million, compared to the consensus revenue estimate of $209.67 million.

4 brokerages have issued twelve-month price objectives for ANI Pharmaceuticals' shares. Their forecasts range from $76.00 to $90.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $84.25 in the next year. This suggests a possible upside of 37.5% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.

Press coverage about ANIP stock has trended very negative this week, according to InfoTrie. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for ANI Pharmaceuticals.

ANI Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 705,700 shares, a decline of 5.6% from the December 15th total of 747,900 shares. Based on an average trading volume of 168,500 shares, the short-interest ratio is currently 4.2 days. Currently, 7.5% of the company's stock are sold short. View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include Genmab A/S (GMAB), Uniqure (QURE), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD), Zogenix (ZGNX), ArQule (ARQL), ChemoCentryx (CCXI), Epizyme (EPZM), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX), Synthorx (THOR) and Xencor (XNCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Broadcom (AVGO), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Celgene (CELG), Cisco Systems (CSCO), NVIDIA (NVDA) and NXP Semiconductors (NXPI).

ANI Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Nisa Investment Advisors LLC (0.06%), Mesirow Financial Investment Management Inc. (0.05%) and Wedge Capital Management L L P NC (0.04%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc.. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

ANIP stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Wedge Capital Management L L P NC. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $61.27.

ANI Pharmaceuticals has a market capitalization of $740.75 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.

The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com/.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]